Resolving Atopic Dermatitis from the Inside out

A next-generation injectable peptide construct targeting the root causes of atopic dermatitis — inflammation, barrier dysfunction, and microbial dysbiosis.

223 Million Patients. A Treatment Ecosystem Built on False Safety.

  • eroids (TCS)

    Front-Line Therapy — With a Hidden Crisis

    • 79% of adult eczema patients report Topical Steroid Withdrawal (TSW) symptoms

    • 81% report intense emotional fluctuations, depression, or anxiety during TSW

    • 80% experience insomnia and sleep disturbances during withdrawal

    • 75% of patients report treatment expectations unmet

    • 57% develop lymphadenopathy during withdrawal

    • 8% of adults experience TSW symptoms for over 5 years after stopping

  • We believe in keeping things simple, smart, and human. Every project starts with listening and ends with something we're proud to share.

  • From startups to seasoned brands, we partner with people who care about doing things right—and doing them well.

Science designed for where atopic dermatitis begins

Kynova Therapeutics is developing a peptide-based therapeutic platform for atopic dermatitis focused on the underlying biology of chronic inflammation and barrier dysfunction.

We are building toward differentiated therapies designed not only to reduce disease activity, but to reflect the complexity of skin disease at the mechanistic level.

Contact Us

Reach out to us using the form here. We value your input and are excited to engage with like-minded individuals, potential partners, and collaborators who share our passion for innovation in peptide therapy for Atopic Dermatitis.